Lecanemab registry and outcome study
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study looks at how well lecanemab (a new Alzheimer's treatment) works in real-world clinics. It also tracks how patients and their care partners do over time. If you are already getting or eligible for lecanemab, you might join with your care partner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a person with Alzheimer's who is eligible to receive lecanemab infusions at a clinic.
- Or you must be a care partner who helps someone with Alzheimer's who is eligible for lecanemab.
- You and your care partner (if applicable) must be at least 18 years old.
- You must be able to read and speak English.
- You must agree to be part of the study by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.